Deutsche Bank Ag\ Theseus Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.12 - $4.18 $34,112 - $67,260	16,091 Added 1849.54%	16,961 $68,000
Q3 2023 Nov 09, 2023	SELL	$2.66 - $10.04 $18,896 - $71,324	-7,104 Reduced 89.09%	870 $2,000
Q2 2023 Aug 14, 2023	SELL	$7.28 - $11.82 $19,437 - $31,559	-2,670 Reduced 25.08%	7,974 $74,000
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $5,845 - $15,764	1,122 Added 11.78%	10,644 $94,000
Q4 2022 Feb 13, 2023	BUY	$4.69 - $8.36 $525 - $936	112 Added 1.19%	9,522 $47,000

Q3 2022 Nov 14, 2022	SELL	$5.7 - $8.68 $6,492 - $9,886	-1,139 Reduced 10.8%	9,410 $55,000
Q2 2022 Aug 11, 2022	BUY	$5.04 - $14.05 $21,651 - $60,358	4,296 Added 68.7%	10,549 $58,000
Q1 2022 May 13, 2022	SELL	$8.75 - $14.51 $6,475 - $10,737	-740 Reduced 10.58%	6,253 $72,000
Q4 2021 Feb 11, 2022	BUY	$8.98 - $20.09 $62,797 - $140,489	6,993 New	6,993 $89,000

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.